Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) is now available.
Biocytogen Pharmaceuticals has successfully completed the issuance of A Shares, which will be listed on the Sci-Tech Innovation Board of the Shanghai Stock Exchange starting December 10, 2025. This strategic move is expected to enhance the company’s market presence and provide additional capital for its operations. In addition, Dr. Zhang Haichao has resigned as an executive director due to internal work adjustments, and Ms. Li Yan has been elected as an employee director, marking a significant leadership change within the company.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a pharmaceutical company based in China, focusing on innovative drug development and biotechnology. The company operates in the pharmaceutical industry with a market focus on biotechnology and drug discovery.
Average Trading Volume: 523,150
Technical Sentiment Signal: Buy
Current Market Cap: HK$12.78B
For a thorough assessment of 2315 stock, go to TipRanks’ Stock Analysis page.